TfRMAb-TNFR treatment altered the expression of disease-associated microglial markers SPP1, a conserved marker of activated/phagocytic microglia in AD mouse and patient brains [54], P2RX7, a purinergic receptor increased in AD brains [68], and ctsd, a lysosomal function marker [54]. This evidence concerns the gene CTSD and Alzheimer disease.